At the Global Journal of Oncology Drug Development and Care (GJODDC), we are committed to providing timely and impactful scholarly content that drives innovation and excellence in oncology pharmacy practice and cancer therapeutics. Browse our current issue and explore our archived volumes for access to high-quality research and clinical advancements.
Featured Articles in the Latest Issue
- Volume 2 (Issue 1) JANUARY- JUNE 2026
Research Articles
Nanostructured Delivery Platforms for Enhancing PARP Inhibitor Localization in Triple-Negative Breast Cancer
Vol.2(1); Pages:1-9. Published on March-2026
Abstract
Triple-negative breast cancer (TNBC) remains one of the most aggressive and therapeutically challenging subtypes of breast malignancies due to the absence of hormone receptors and HER2 expression. This study investigates the development of a targeted nanocarrier system for the efficient delivery of poly (ADP-ribose) polymerase (PARP) inhibitors, aiming to enhance therapeutic efficacy while minimizing systemic toxicity. Lipid-polymer hybrid nanoparticles were engineered and functionalized with folate ligands to improve tumor specific uptake. In vitro cytotoxicity assays demonstrated significantly enhanced drug accumulation and apoptosis induction in TNBC cell lines compared to free drug administration. In vivo murine models further confirmed improved tumor regression and reduced off-target effects. Pharmacokinetic profiling indicated prolonged circulation time and improved bioavailability of the encapsulated drug. The results highlight the potential of nanocarrier-based targeted delivery systems in overcoming current limitations of PARP inhibitor therapy. This approach offers a promising avenue for personalized treatment strategies in TNBC and warrants further clinical investigation to validate translational applicability.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Immunotherapeutic Synergy of PD-1 Blockade and Oncolytic Viruses in Advanced Melanoma
Vol.2(1); Pages:10-18. Published on April-2026
Abstract
Advanced melanoma has shown responsiveness to immune checkpoint inhibitors; however, resistance remains a significant barrier. This randomized controlled trial evaluates the therapeutic synergy between programmed cell death protein 1 (PD-1) blockade and oncolytic viral therapy. A cohort of 120 patients with stage III–IV melanoma was divided into two treatment arms: PD-1 inhibitor monotherapy and combination therapy with an engineered oncolytic herpes simplex virus. Clinical endpoints included overall survival, progression-free survival, and immune response biomarkers. The combination therapy group exhibited a statistically significant improvement in tumor regression rates and median survival outcomes. Immunological assays revealed enhanced T-cell infiltration and cytokine activation within the tumor microenvironment. Adverse effects were manageable and comparable between groups. These findings support the hypothesis that oncolytic viruses can potentiate immune checkpoint therapy by enhancing tumor immunogenicity. The study underscores the importance of combinatorial approaches in overcoming immune resistance and improving patient outcomes in advanced melanoma.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Pharmacogenomic Profiling in Predicting Chemotherapy Response in Colorectal Cancer Patients
Vol.2(1); Pages:19-26. Published on April-2026
Abstract
Variability in chemotherapy response among colorectal cancer patients has prompted interest in pharmacogenomic profiling as a predictive tool. This observational cohort study assesses the relationship between genetic polymorphisms and treatment outcomes in patients receiving standard fluoropyrimidine-based chemotherapy. Genomic DNA from 200 patients was analyzed for variants in genes associated with drug metabolism, transport, and DNA repair pathways. Clinical response was evaluated based on tumor shrinkage, progression-free survival, and incidence of adverse drug reactions. The study identified significant associations between specific polymorphisms in DPYD and TYMS genes and both therapeutic efficacy and toxicity profiles. Patients with high-risk genotypes exhibited increased adverse effects and reduced treatment response. These findings demonstrate the clinical utility of pharmacogenomic screening in optimizing chemotherapy regimens and minimizing toxicity. Implementation of such personalized approaches could enhance treatment precision and improve overall patient prognosis in colorectal cancer management.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Selective Targeting of KRAS G12C in Lung Adenocarcinoma Using Rational Small Molecule Design
Vol.2(1); Pages:27-34. Published on May-2026
Abstract
KRAS mutations, particularly the G12C variant, are prevalent in lung adenocarcinoma and have historically been considered undruggable targets. This study reports the design and evaluation of novel small molecule inhibitors specifically targeting the KRAS G12C mutation. Structure-based drug design techniques were employed to develop compounds capable of selectively binding to the mutant KRAS protein. In vitro assays demonstrated potent inhibition of KRAS signaling pathways, leading to reduced cell proliferation and increased apoptosis in mutant cell lines. In vivo xenograft models confirmed significant tumor growth suppression with minimal systemic toxicity. Molecular docking and binding affinity analyses supported the specificity and stability of the inhibitor-protein interaction. These findings represent a significant advancement in targeted cancer therapy, offering new therapeutic options for patients with KRAS-mutant lung cancers. Further clinical studies are required to evaluate safety and efficacy in human populations.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Microbiome-Driven Modulation of Chemotherapy Response in Pancreatic Cancer
Vol.2(1); Pages:35-45. Published on May-2026
Abstract
Pancreatic cancer is characterized by poor prognosis and limited responsiveness to conventional chemotherapy. Emerging evidence suggests that the gut microbiome plays a crucial role in modulating drug efficacy and host immune responses. This translational study explores the impact of microbiome modulation on chemotherapy outcomes in pancreatic cancer. Using both patient-derived samples and murine models, the study assessed the effects of probiotic supplementation and antibiotic-mediated microbiome alteration on gemcitabine efficacy. Results indicated that specific microbial profiles were associated with enhanced drug response and reduced tumor progression. Mechanistic investigations revealed that microbiome modulation influenced immune activation and altered drug metabolism pathways. Patients with favorable microbiome compositions demonstrated improved clinical outcomes and reduced treatment-related toxicity. These findings highlight the potential of integrating microbiome-targeted interventions into cancer treatment protocols. The study provides a foundation for future clinical trials aimed at leveraging microbiome dynamics to improve therapeutic efficacy in pancreatic cancer.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
